Johnson & Johnson spotlighted its EYE-RD Global Registry at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting held in Seattle in May.
The first-of-its-kind observational, non-interventional global IRD registry created to make clinical information on IRDs more accessible to patients, providers, payers and researchers. The registry served as a centralised repository of longitudinal data collected on genetically tested patients who were diagnosed or had a suspected diagnosis of IRDs such as X-linked retinitis pigmentosa, a rare IRD estimated to impact one in 40,000 people globally. The registry had the potential to bridge the knowledge gap in IRDs through the collection of real-world data by collating more holistic insights about disease progression and patient experiences.
“At Johnson & Johnson, we are committed to preserving vision, harnessing the best science to find solutions for those living with blinding retinal diseases,” said Hideo Makimura, M.D., Ph.D., Vice President and Global Head, Specialty Ophthalmology Research and Development, Johnson & Johnson Innovative Medicine. “The data at ARVO 2024 showcase our commitment to bringing innovative new therapies that preserve and restore vision for patients worldwide.”
The company also hosted two oral presentations, one evaluating the role of automatic Deep Learning based algorithms to measure precursors of geographic atrophy (GA), a late-stage and severe form of age-related macular degeneration (AMD).